文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌大分割高剂量放疗4周与5周方案:随机三期试验中期安全性分析

4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-12-19

这项单中心三期随机试验将160例局限性前列腺癌患者按1:1分配至56 Gy/16次(A臂)或67 Gy/25次(B臂),预设中期分析显示两臂急性≥2级胃肠道毒性分别为21/77例和16/82例,均未达到预设剔除标准,两种大分割方案均可认为安全。

要点

  • A臂急性2级和3级胃肠道毒性分别为20例(26%)和1例(1%)。
  • B臂急性2级胃肠道毒性16例(20%),未报告3级。
  • 两臂泌尿毒性以2级为主,毒性在放疗期间达峰、放疗后数月缓解。

核心结论

  • A臂急性≥2级胃肠道毒性21/77例、B臂16/82例,两种大分割方案均可认为安全。

研究设计与样本

  • 单中心三期随机试验,2013年6月至2016年7月纳入160例前列腺癌患者,按1:1随机分配至56 Gy(16次×3.5 Gy,A臂)或67 Gy(25次×2.68 Gy,B臂)。
  • 随机化采用计算机生成区组,按既往经尿道前列腺切除术和优势前列腺内病灶分层;治疗分配未设盲,临床医生未设盲。
  • 主要终点为急性胃肠道毒性,采用CTCAE 4.0版和RTOG毒性量表评估;预设160例时进行急性毒性中期分析。
  • 若72例中≥22例出现≥2级胃肠道毒性则剔除该研究臂;试验注册号NCT01921803。

主要发现

  • A臂20例(26%)发生急性2级、1例(1%)发生3级胃肠道毒性;B臂16例(20%)报告急性2级胃肠道毒性。
  • A臂42例(55%)和5例(6%)分别发生急性2级和3级泌尿毒性;B臂40例(49%)和7例(9%)分别报告急性2级和3级泌尿毒性。
  • 毒性在放疗期间达峰,并在放疗后数月内缓解。

关键数值与推荐

  • A臂急性≥2级胃肠道毒性21/77例,B臂16/82例,均低于预设的剔除阈值(72例中≥22例)。
  • A臂剂量为56 Gy分16次、每次3.5 Gy;B臂剂量为67 Gy分25次、每次2.68 Gy。

临床怎么用

  • 中期安全性结果支持两种大分割方案用于局限性前列腺癌的临床实施,方案选择可结合毒性谱与资源条件。
  • 放疗期间及放疗后数月应重点监测胃肠道和泌尿毒性。

局限性

  • 本文为中期安全性分析,治疗分配未设盲、临床医生未设盲,疗效终点尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hypofractionated radiation therapy (HFRT) for localized prostate cancer is safe and effective. The question that remains is which hypofractionation schedule to implement. We compared 2 different HFRT regimens in the present study. METHODS AND MATERIALS: From June 2013 to July 2016, 160 patients with prostate cancer were randomly assigned (1:1), within this single-center phase III trial, to 56 Gy (16 fractions of 3.5 Gy; arm A) or 67 Gy (25 fractions of 2.68 Gy; arm B). Randomization was performed using computer-generated permuted blocks, stratified by previous transurethral resection of the prostate and the presence of a dominant intraprostatic lesion. Treatment allocation was not masked, and the clinicians were not blinded. The primary endpoint was acute gastrointestinal (GI) toxicity, assessed using the Common Terminology Criteria for Adverse Events, version 4.0, and Radiation Therapy Oncology Group toxicity scale. An interim analysis of acute toxicity was planned at 160 patients to prove the safety of both treatment regimens. If ≥22 of 72 patients had grade ≥2 GI toxicity, the study arm would be rejected. The study is registered at ClinicalTrials.gov (NCT01921803). RESULTS: In arm A, 20 patients (26%) and 1 patient (1%) developed acute grade 2 and grade 3 GI toxicity. In arm B, 16 patients (20%) reported acute grade 2 GI toxicity. In arm A, 42 (55%) and 5 (6%) patients developed acute grade 2 and grade 3 urinary toxicity. In arm B, 40 (49%) and 7 (9%) patients reported acute grade 2 and grade 3 urinary toxicity. Toxicity peaked during radiation therapy and resolved in the months after radiation therapy. CONCLUSIONS: With acute grade ≥2 GI toxicity reported in 21 of 77 patients in arm A and 16 of 82 patients in arm B, both treatment arms can be considered safe.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Fonteyne V, Sarrazyn C, Swimberghe M, et al. 4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2017. PMID: 29485064. doi:10.1016/j.ijrobp.2017.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。